The Filing Desk

Puma Biotechnology vs Stoke Therapeutics

Puma Biotechnology PBYI · Stoke Therapeutics STOK · Pharmaceuticals

Puma Biotechnology reported revenue of $228 million in fiscal 2025, 1.2 times Stoke Therapeutics' $184 million in fiscal 2025. Puma Biotechnology's revenue fell 0.9% in its latest year, and Stoke Therapeutics' grew 404.5%. Puma Biotechnology had an operating margin of 16.3%, against -11.2% at Stoke Therapeutics. Free cash flow was $42 million at Puma Biotechnology and $45 million at Stoke Therapeutics.

Side by side

Puma BiotechnologyStoke Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$228M$184M
Revenue growth−0.9%404.5%
Revenue growth a year, last 5 years0.3%—
Gross margin74.5%—
Operating margin16.3%−11.2%
Net margin13.6%−3.7%
Free cash flow$42M$45M
Free cash flow margin18.3%24.4%
Return on capital48.2%—
Net debt to EBITDA−1.4x—
Dividends and buybacks$0M$0M
Change in diluted share count3.2%9.7%
Last close$7.77$26.68
P/E at the last close16.9×—
Insider trades, last 12 months—sold $8.7 million
Piotroski F-score8 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Puma BiotechnologyStoke Therapeutics
Operating margin
Percent of revenue
Puma BiotechnologyStoke Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Puma BiotechnologyStoke Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Puma Biotechnology and Stoke Therapeutics pages.